Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23055516 | 0.91 | RET (0.35) | HRH3AXLMAPK1PRMT5WDR77 | |
| SCHEMBL23055862 | 0.90 | PARP14 (0.32) | MAPK1PRMT5WDR77 | |
| SCHEMBL23055413 | 0.89 | LMNA (0.33) | MAPK1PRMT5WDR77 | |
| SCHEMBL23055624 | 0.89 | PRKCQ (0.34) | PRMT5WDR77 | |
| SCHEMBL23055872 | 0.88 | HRH3 (0.41) | HRH3MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL23055521 | 0.87 | DDB1 (0.36) | HRH3MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL23055903 | 0.87 | PRMT5 (0.34) | PRMT5WDR77 | |
| SCHEMBL23055402 | 0.86 | BRD4 (0.31) | — | |
| SCHEMBL23056167 | 0.86 | MAPK13 (0.37) | MAPK13MAPK12MAPK11MAPK14ITGB2 | |
| SCHEMBL23055393 | 0.86 | PRMT5 (0.34) | AXLMAPK1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795147-B2 | Modulators of complex I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-11795147-B2 | Modulators of complex I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-20210061761-A1 | MODULATORS OF COMPLEX I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061761-A1 | MODULATORS OF COMPLEX I | NDUFAB1, NDUFV1, NDUFB7 | HRH3 4750/4885MAPK13 3264/4885MAPK12 2600/4885 |
| US-11795147-B2 | Modulators of complex I | NDUFAB1, NDUFV1, NDUFB7 | HRH3 4750/4885MAPK13 3264/4885MAPK12 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.